319 related articles for article (PubMed ID: 36866921)
1. Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic fibrosis.
Aslam AA; Sinha IP; Southern KW
Cochrane Database Syst Rev; 2023 Mar; 3(3):CD012040. PubMed ID: 36866921
[TBL] [Abstract][Full Text] [Related]
2. Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic fibrosis.
Aslam AA; Higgins C; Sinha IP; Southern KW
Cochrane Database Syst Rev; 2017 Jan; 1(1):CD012040. PubMed ID: 28102546
[TBL] [Abstract][Full Text] [Related]
3. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.
Patel S; Sinha IP; Dwan K; Echevarria C; Schechter M; Southern KW
Cochrane Database Syst Rev; 2015 Mar; (3):CD009841. PubMed ID: 25811419
[TBL] [Abstract][Full Text] [Related]
4. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.
Skilton M; Krishan A; Patel S; Sinha IP; Southern KW
Cochrane Database Syst Rev; 2019 Jan; 1(1):CD009841. PubMed ID: 30616300
[TBL] [Abstract][Full Text] [Related]
5. Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis.
Southern KW; Patel S; Sinha IP; Nevitt SJ
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD010966. PubMed ID: 30070364
[TBL] [Abstract][Full Text] [Related]
6. Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del).
Southern KW; Murphy J; Sinha IP; Nevitt SJ
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD010966. PubMed ID: 33331662
[TBL] [Abstract][Full Text] [Related]
7. Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del).
Heneghan M; Southern KW; Murphy J; Sinha IP; Nevitt SJ
Cochrane Database Syst Rev; 2023 Nov; 11(11):CD010966. PubMed ID: 37983082
[TBL] [Abstract][Full Text] [Related]
8. Topical cystic fibrosis transmembrane conductance regulator gene replacement for cystic fibrosis-related lung disease.
Lee TW; Southern KW; Perry LA; Penny-Dimri JC; Aslam AA
Cochrane Database Syst Rev; 2016 Jun; 2016(6):CD005599. PubMed ID: 27314455
[TBL] [Abstract][Full Text] [Related]
9. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
10. Macrolide antibiotics (including azithromycin) for cystic fibrosis.
Southern KW; Solis-Moya A; Kurz D; Smith S
Cochrane Database Syst Rev; 2024 Feb; 2(2):CD002203. PubMed ID: 38411248
[TBL] [Abstract][Full Text] [Related]
11. Exercise versus airway clearance techniques for people with cystic fibrosis.
Heinz KD; Walsh A; Southern KW; Johnstone Z; Regan KH
Cochrane Database Syst Rev; 2022 Jun; 6(6):CD013285. PubMed ID: 35731672
[TBL] [Abstract][Full Text] [Related]
12. Psychological interventions for improving adherence to inhaled therapies in people with cystic fibrosis.
Dawson S; Girling CJ; Cowap L; Clark-Carter D
Cochrane Database Syst Rev; 2023 Mar; 3(3):CD013766. PubMed ID: 36989170
[TBL] [Abstract][Full Text] [Related]
13. Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial.
Kerem E; Konstan MW; De Boeck K; Accurso FJ; Sermet-Gaudelus I; Wilschanski M; Elborn JS; Melotti P; Bronsveld I; Fajac I; Malfroot A; Rosenbluth DB; Walker PA; McColley SA; Knoop C; Quattrucci S; Rietschel E; Zeitlin PL; Barth J; Elfring GL; Welch EM; Branstrom A; Spiegel RJ; Peltz SW; Ajayi T; Rowe SM;
Lancet Respir Med; 2014 Jul; 2(7):539-47. PubMed ID: 24836205
[TBL] [Abstract][Full Text] [Related]
14. Inhaled anti-pseudomonal antibiotics for long-term therapy in cystic fibrosis.
Smith S; Rowbotham NJ
Cochrane Database Syst Rev; 2022 Nov; 11(11):CD001021. PubMed ID: 36373968
[TBL] [Abstract][Full Text] [Related]
15. Nebulised hypertonic saline for cystic fibrosis.
Wark P; McDonald VM; Smith S
Cochrane Database Syst Rev; 2023 Jun; 6(6):CD001506. PubMed ID: 37319354
[TBL] [Abstract][Full Text] [Related]
16. Short-acting inhaled bronchodilators for cystic fibrosis.
Smith S; Rowbotham NJ; Edwards CT
Cochrane Database Syst Rev; 2022 Jun; 6(6):CD013666. PubMed ID: 35749226
[TBL] [Abstract][Full Text] [Related]
17. Nebulised hypertonic saline for cystic fibrosis.
Wark P; McDonald VM
Cochrane Database Syst Rev; 2018 Sep; 9(9):CD001506. PubMed ID: 30260472
[TBL] [Abstract][Full Text] [Related]
18. Probiotics for people with cystic fibrosis.
Coffey MJ; Garg M; Homaira N; Jaffe A; Ooi CY
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD012949. PubMed ID: 31962375
[TBL] [Abstract][Full Text] [Related]
19. Bronchoscopy-guided antimicrobial therapy for cystic fibrosis.
Jain K; Wainwright CE; Smyth AR
Cochrane Database Syst Rev; 2024 May; 5(5):CD009530. PubMed ID: 38700027
[TBL] [Abstract][Full Text] [Related]
20. Active cycle of breathing technique for cystic fibrosis.
Wilson LM; Saldanha IJ; Robinson KA
Cochrane Database Syst Rev; 2023 Feb; 2(2):CD007862. PubMed ID: 36727723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
